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■ Abstract
Recombinant and purifi ed allergens are currently available for determining specifi c IgE targeted to different allergenic components. In this 
way it is possible to diagnose the sensitization profi le of each individual patient. The microarray technique makes it possible to determine 
specifi c IgE against multiple allergens simultaneously in one same patient, with a minimum amount of serum, and even allows the 
determination of IgG and IgM against the same allergens in one same serum sample. Microarray procedures are being developed not only 
for the determination of antibodies but also for cell activation tests. In addition, microarray technology will help explain cross-reactions, and 
will facilitate the evaluation of subjects in which skin tests cannot be performed. These techniques will allow a great step forward in the 
development of immunotherapy specifi cally targeted to the sensitizations found in each individual patient, yielding especially hypoallergenic 
forms of great immunogenic capacity, and thus improving the safety and effi cacy of immunotherapy. Lastly, microarrays will improve our 
understanding of the physiopathology of allergic diseases.
Key words: Microarrays, diagnosis by components, specifi c IgE, immunotherapy.
Molecular diagnosis in Allergology:
application of the microarray tecnique
M Ferrer,1 ML Sanz,1 J Sastre,2,3 J Bartra,4,3 A del Cuvillo,5 J Montoro,6 
I Jáuregui,7 I Dávila,8 J Mullol,9,3 A Valero4,3
1 Departamento de Alergia e Inmunología Clínica, Clínica Universidad de Navarra, Pamplona, Spain
2 Servicio de Alergia, Fundación Jiménez Díaz, Madrid, Spain
3 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES)
4 Unitat d’Al.lèrgia, Servei de Pneumologia i Al.lèrgia Respiratòria, Hospital Clinic (ICT), Barcelona, Spain
5 Clínica Dr. Lobatón, Cádiz, Spain
6 Unidad de Alergia, Hospital La Plana, Vila-Real (Castellón), Spain
7 Servicio de Alergología, Hospital de Basurto, Bilbao, Spain
8 Servicio de Inmunoalergia, Hospital Universitario, Salamanca, Spain
9 Unitat de Rinologia & Clínica de l’Olfacte, Servei d’Oto-rino-laringologia, Hospital Clínic
  Immunoal.lèrgia Respiratòria Clínica i Experimental, IDIBAPS. Barcelona, Spain
■ Resumen
En el momento actual la disponibilidad de alérgenos recombinantes y purifi cados permite determinar IgE específi ca frente a diversos 
componentes alergénicos. De esta manera es posible diagnosticar el perfi l de sensibilización individual de cada paciente. La técnica de las 
micromatrices (microarrays) permite determinar IgE específi ca frente a múltiples alérgenos a un tiempo en un mismo paciente con una 
mínima cantidad de suero e incluso permite en una misma muestra de suero determinar IgG e IgM frente a los mismos alérgenos. Ya se 
están desarrollando no sólo determinaciones de anticuerpos sino ensayos de activaciones celulares en micromatrices. Además ayudará a 
explicar reacciones cruzadas, facilitará realizar una evaluación a sujetos en los que no podemos realizar pruebas cutáneas. Va a signifi car 
un gran impulso para el desarrollo de la Inmunoterapia dirigida exactamente a las sensibilizaciones de cada paciente, consiguiendo formas 
especialmente hipoalergénicas con gran poder inmunogénico, mejorando la seguridad y la efi cacia de la inmunoterapia. Finalmente, estas 
técnicas van a facilitar la comprensión de la fi siopatología de las enfermedades alérgicas.
Palabras clave: Micromatrices. Microarray. Diagnóstico por componentes. IgE específi ca. Inmunoterapia.
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Introduction
When speaking of new diagnostic methods, it is good not to 
lose sight of the historical perspective. In the 1930s, Alexander 
Francis stated that “Skin tests are simple and fascinating; and 
the vaccines used to immunize against the protein found to be 
the cause of the symptoms became so popular as a universal 
treatment that the cure for all forms of asthma was believed 
to be at hand” [1]. Years later, the discovery of IgE generated 
controversy between those who defended the reliability of 
skin testing and those who supported in vitro diagnosis – to 
the point that an editorial claimed that the determination of 
specifi c IgE would “quickly replace the primitive skin tests 
in clinical practice” [2]. 
Perhaps the same will happen with molecular diagnosis. 
However, it is clear that the steps taken by Charles Blakely 
in investigating his own pollinosis by performing a pollen 
skin test on himself, or by Kimishige and Teruko Ishizaka 
on one hand and Johansson on the other in discovering IgE, 




In the late 1980s, when the fi rst allergen was cloned [3], a 
new era was opened for the production of purifi ed recombinant 
allergens of use in diagnosis and treating allergic diseases [4].
Up until that time it was possible to determine the 
allergenic source to which a given patient was sensitive. 
With the application of molecular or components diagnostic 
techniques it is possible to defi ne the individual sensitization 
profi le, i.e., we can establish what parts of the allergen are 
recognized by each individual patient. In recent years we have 
seen the characterization and production of the most relevant 
allergens at molecular level, and most have been generated as 
recombinant proteins [5, 6]. However, the different new purifi ed 
recombinant allergens have steadily increased in number, and 
it is almost impossible to study all the recombinants of related 
families in one same patient. 
Subsequently, effort focused (and remains centered) on 
the confi rmation that the available recombinant allergens 
or natural allergens are those truly recognized by the 
patient IgE, and that they trigger symptoms. The aim is to 
establish that they possess an IgE epitope recognition profi le 
similar to that of the allergens that had been studied to date. 
Furthermore, determinations are being made to establish 
that the allergens panel is representative of a given type of 
sensitization [7]. 
Principles of the technique
Microarrays or biochips were developed as a tool for 
analyzing gene expression in genomes. Since their introduction 
in the early 1990s, DNA microarray technology has been applied 
to the determination of nucleic acid, and this in turn was followed 
by analysis of the expression of RNA. This step was needed 
among other reasons because the exploration of gene expression 
required increasingly effective tools for studying protein 
expression at intracellular level. The microarray technique for 
proteins was thus developed, adopting the same microarray 
technology initially used in application to DNA.
Microarray technique is a solid phase multiple immunoassay 
in which the proteins (purified recombinant or natural 
allergens) are immobilized in a solid phase, and minimal 
amounts of serum are incubated with these proteins under 
standardized conditions. The antibodies present in the serum 
are captured by the different allergens, and following a washing 
step to eliminate the unbound substances, the antibodies 
are detected by means of a second fl uorescent-labeled anti-
isotype antibody or an enzyme that is detected by laser or 
chemiluminescence.
To date, specifi c IgE has been determined on an individual 
allergen-by-allergen basis. With this technique, multiple 
allergenic components are determined in one same serum 
sample, and it also allows to determine in the same serum 
sample not only IgE but also IgG, IgM and IgA simultaneously, 
and targeted to the same allergens.
As in the case of the DNA microarrays, the technique is 
performed on solid surfaces such as high-quality glass slides 
of the same kind used in light microscopy. For immobilization 
of the protein on the slide [8, 9], the surface is modifi ed, 
for example with nitrocellulose or gel-like structures. The 
different types of protein (recombinant, antibodies, peptides or 
heptamers) are deposited in micrometric spaces using robotics 
(at present this allows us to deposit up to 30,000), followed 
by reaction with the ligand. This binding reaction in turn is 
detected by fl uorescent-labeled antibodies, stains or combined 
techniques. Fluorescence is usually detected by laser. In order 
to calculate and analyze the results on a semiquantitative 
basis, software is needed to compare the fl uorescence of the 
test allergens with a known IgE concentrations curve, used to 
extrapolate the test result.
In general, the entire process lasts no more than fi ve hours, 
and poses no technical diffi culties. The number of patients 
depends on the number of slides processed at the same time. 
In the case of specifi c IgE, based on the technique used by the 
authors of the VBC-Genomics prototype, each slide can be used 
to analyze up to four patients.
Figure. The steps of the technique comprise prior washing to eliminate 
all non-covalent bonds to the allergens, followed by the addition 
of 50 µl of serum and incubation. After a brief washing step, the 
fluorescent-labeled antibody is added, and the glass is laser-scanned 
after a second washing step.
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Table 1. List of available allergens
                                     Foods                                                          Trees                              Dust mites Latex
Kiwi nAct d 1 Aln g 1.0101 Der f 1 Hev b 10.0102   Der f 2 
 nAct d 2 Bet v 1.0101 Der p 1 Hev  b 6.02
 nAct d 5 Bet v 1.0401 Der p 2 Hev b 7.02
 nAct d 8 Bet v 2.0101 Der p 10.0101 Hev b 8.0204
 nAct d 1 Cor a 1.0103 Der s 1 Hev b 11.0101
 nAct d 2 Cup a 1  Hev b 1.0101
  Ole e 1  Hev b 3.0101
   Animal epithelia
Celery Api g 1.0101 Ole e 2 Can f 1 Hev b 5.0101
  Pho d 2.0101 Can f 3 Hev b 0.0101
   
Milk Bos d 4 Pla a 2 Fel d 1 
 Bos d 6 Pla a 1.0101
 Bos d 7  Fungi
 Bos d 8 
Grasses
 Alt a 1.0101
 Bos d Lactoferrin Cyn d 12.0101 Alt a 6.0101
 Bos d 8 alpha S1 Lol p 1 Asp f 1
 Bos d 8 beta Phl p 1.0102 Cla h 8.0101
 Bos d 8 kappa Phl p 5.0101 
 Bos d 5.0102 Phl p 12.0101
 Bos d 5.0101 Phl p 2.0101 
Cockroach
 Cor a 8 Phl p 6.0101 Bla g 2.0101
   Bla g 5.0101
Carrot Dau c 1.0103 Phl p 7.0101 Per a 7.0101 
Egg Gal d 1  
 Gal d 2
 Gal d 3 
Weeds
 Gal d 4 Art v 1 
Anisakis
 Gal d 5 Hel a 2.0101 Ani s 3.0101
   Ani s 1.0101
Apple Mal d 1.0108 Mer a 1.0101 
Shrimp Pen i 1 Par j 1.0103
 Pen m 1 Par j 2.0101 Hymenoptera
  Par j 3.0102
Peach Pru p 1 
 Pru p 3  Api m 1
   Api m 4
Wheat Tri a 18  
 Tri a 19 Gliadin CCD marker* 
 Tri a 19.0101 Ana c 2
 Tri a aA_TI
Cashew nuts Ana o 2.0101
Sesame nSe s i1
Brazil nut rBe re 1
Peanut nAra h 1
 nAra h 2
 nAra h 3
 rAra h8
Hazelnut rCor a 1.0401 
 rCor a 8
 nCor a 9
Soya rGly m 4
 NGly m b-conglycinin
 nGly m glycin 
* Carbo-hydrate Cross Determinants.
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The concept of a protein ligand reaction was published for 
the fi rst time 15 years ago [10]. Such ligand reactions were not 
possible in the past because of the diffi culty of immobilizing 
proteins in such small spaces, due to their size, charge and 
three-dimensional structure. It was not until 10 years later 
when the use of microarrays with raw allergen on conventional 
glass slides was fi rst published, using signal amplifi cation 
[11]. Subsequently, Kim et al. performed the technique on a 
nitrocellulose base chip [12]. In addition, mention must be made 
of the diffi culty posed by possible protein denaturalization during 
the immobilization process, and of the fact that recognition by 
IgE requires preservation of the tertiary structure.
In sum, the technique constitutes a specific IgE 
semiquantitative indirect enzymoimmunoassay (EIA). 
The main advantage with respect to other methods is that 
we can perform multiple determinations of specifi c IgE 
targeted to a panel of allergenic components which can 
be expanded. The technique recognizes the patient IgE 
by means of a fl uorescence-labeled secondary antibody. 
As commented above, a panel of recombinant or natural 
allergens is immobilized on a chip with dimensions that allow 
easy handling (the size of a glass slide). With the currently 
available technique, each allergen is bound to the slide in 
triplicate, to ensure reproducibility of the test. The amount 
of serum required is 50 ml, together with the calibrators. 
Each well containing the allergen is surrounded by Tefl on to 
prevent spillage of the sample. Each well contains the same 
amount of allergen, in case dilutions are posteriorly to be 
studied. The number of allergens that can be immobilized by 
means of this technique is practically unlimited. 
Correlation with determination of 
specifi c IgE 
A number of studies have explored the correlation of 
the microarray technique and the different methods used 
to date. The fi rst study compared the microarray technique 
developed by VBC-Genomics with the Phadia CAP system for 
determination of specifi c IgE for three allergens corresponding 
to grasses, birch and dust mites, and reported a correlation of 
0.9 [13]. Lebrun [14] published the results obtained with a 
colorimetric technique applied to common allergens, detecting 
specifi c IgE levels lower than the cut-off point accepted for 
the conventional technique (0.35 Ku/l).
More recently, Wöhrl et al. [15] published their results 
comparing microarrays with the version CRD-50 ISAC 
technique, produced by VBC-Genomics, and the Phadia 
UniCAP. The diagnosis of recombinants was shown to be as 
sensitive as the diagnosis of complete allergen determination 
with the UniCAP for patients allergic to grasses, cats and birch. 
Sensitivity with dust mites was lower, but remained high (in the 
same way as specifi city), and was likewise seen to be lower for 
the detection of patients sensitive to Artemisia.
Benefi ts
The benefi ts of the technique are summarized in Table 2.
The main advantage of the technique is that it allows 







Need for only scant allergen
Scalability
Automatization
to analyze hundreds of allergens at the same time, with a 
minimum amount of sample (only 50 ml of serum), and 
involving a single analysis. In the case of VCB-genomics, the 
fi gure is presently 103 allergens per chip (the list of allergens is 
shown in Table 1). The technique makes it possible to expose 
the greatest possible number of recognizable epitopes to IgE. 
The technique also allows to analyze different fl uorescences; 
as a result, in one same test it could be possible to measure 
specifi c IgE and IgG. 
A second benefi t of the technique is that it facilitates 
component-based diagnosis [15-17]. This fact offers a 
greater curacy in establishing which allergen is recognized 
by a given patient, helping to explain cross-reactions, and 
resolving enigmas such as patients with positivity to multiple 
pollens to which they have never been exposed and which are 
apparently scantly related (the explanation in such cases being 
sensitization to panallergens). With the traditional methods 
it would be practically impossible to analyze the panel of 
recombinants and natural allergens ensuring the presentation 
of a signifi cant number of epitopes. On the other hand, the 
molecules might not present the same immune reactivity as 
the complete natural allergen. 
Another important benefi t of this technique is that it allows 
the screening of individuals in whom skin tests cannot be made, 
such as patients with severe atopic dermatitis, dermographism 
or children, or cases in which the intensity of the reaction 
precludes skin testing.
Immunotherapy
A field in which the contribution of the microarray 
technique will be crucial is the development of the composition 
of immunotherapy. To date, immunotherapy composition 
consisted in allergen extracts, comprising mixtures of 
allergenic and non-allergenic components. These formulations 
are diffi cult to standardize and do not adapt to the sensitization 
profi le of each individual patient. Immunotherapy currently 
can contain allergens to which the patient is not sensitive, 
or may contain insuffi cient doses of those allergens that are 
relevant to the patient. More importantly, the formulation used 
may lack precisely those components to which the patient is 
most sensitive. Lastly, immunotherapy with complete extracts 
possesses allergenic potential in addition to immunogenic 
potential, and this entails a risk of hypersensitivity reactions.
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A number of studies have shown that immunotherapy 
targeted to recombinant allergens is both effective and 
safe [18-21], and moreover allows the use of especially 
hypoallergenic forms with great immunogenic potential. As 
a result, in the near future the quality, safety and effi cacy 
of immunotherapy will be enhanced [21]. In addition, 
such procedures will allow to explore the mechanism of 
immunotherapy. 
To this effect it is necessary to demonstrate that such 
formulations possess the same potency as the complete 
natural allergens, and that the panel of recombinant allergens 
encompasses all the epitopes recognized by the B and T cells. 
In the case of grasses, it has been shown that a panel of 5 
recombinants (Phl p 1, Phl p 2, Phl p 5a, Phl p 5b) [22], or the 
mentioned panel plus Phl p 6 [23], signifi cantly reduces the 
symptoms and induces a specifi c and very intense IgG mediated 
response against these allergens [24]. Birch allergens behave 
in a similar manner.
Although dust mite allergens yield a much greater number 
of recombinants, it also has been shown that by combining 
a panel of recombinants we can fully inhibit IgE binding to 
the complete allergen [25]. It is thus shown that recombinant 
allergens can substitute the natural extract, and that several 
recombinants suffi ce to establish the diagnosis. In patients 
sensitized to dust mites, the technique already allows us to 
determine whether they are sensitized to group 1 or two group 
2 allergens, or whether in contrast the subjects are sensitized 
to tropomyosin – which would constitute a contraindication 
to immunotherapy with dust mite extracts containing group 
1 and 2 allergens.
It has even been shown that recombinant hybrids from 
unrelated allergenic sources possess great immunogenic 
capacity [26].
Other applications of the microarrays 
technique in Allergology are commented 
below
An innovating application of the microarray technique 
in allergological diagnosis has recently been published [27]. 
The procedure is based on the basophil activation test, which 
consists of analyzing the expression of basophil activation 
markers such as CD63, following stimulation with different 
allergens [28, 29]. The authors eliminated IgE from mature 
human basophils and from a basophilic cell line, followed 
by resensitization of the cells with serum from patients 
with allergy to grasses. This in turn was followed by the 
determination of CD63 expression after incubation. The 
authors moreover found that the cell line responds in the same 
way as the adult basophils in peripheral blood. These results 
need to be reproduced and confi rmed by other investigators, 
though they illustrate the potential for development of 
microarray technology.
Basophil immobilization was achieved with the development 
of microarrays for typing leukemias
This technique, in which the presence of specifi c IgE does 
not necessarily imply that it is able to bridge the IgE receptors 
of basophils and mast cells and thus trigger symptoms, 
only indicates the existence of sensitization. The technique 
quantifi es basophil activation in response to a given allergen via 
binding to the specifi c IgE present in the serum of the studied 
patient – not only the presence in serum of specifi c IgE.
Future applications
One future application will be the identifi cation of new 
patients previously classifi ed as being non-allergic individuals, 
since some recombinant allergens are not present in the 
allergenic extracts used to date.
Regarding food allergy, the potential is particularly 
important, since panels could be developed that include at 
least the overall proteins to which we are exposed in a given 
diet, or to which patients from a given geographical setting 
are most exposed. This is being done with diets in the United 
Kingdom, for example [30].
Lastly, the technique may serve to establish predictive 
values for the symptoms severity, as is already being done 
for LTPs and anaphylaxis, or for the probability that food 
sensitization in children will be grown. Another possibility is 
the defi nition of adequate immunotherapy composition.
Ideally, and in addition to the required reproducibility 
and reliability of the technique, an in vitro diagnostic method 
should be minimally invasive – allowing the clinician to collect 
extensive and applicable information. 
The technique requires validation and the conduction of 
further studies with large population cohorts, and correlates 
results with clinical symptom. We should avoid blind 
enthusiasm, but  in the meanwhile we should seize the 
oportunity as Allergists.
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